The planned workforce reduction at Syros Pharmaceuticals could lead to short-term disruptions in operations, potentially affecting the company's stock price negatively in the short term. However, the move is aimed at focusing resources on the late-stage development of Tamibarotene, which could improve the company's long-term financial stability and potentially lead to a positive impact on the stock price in the long term.